[Ac 225]RTX-2358 / Ratio Therap - LARVOL DELTA

Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas (PRNewswire) - "The ATLAS trial is a Phase 1/2 open-label clinical trial...designed to assess the safety, tolerability, dosimetry, biodistribution, pharmacokinetics, and preliminary anti-tumor activity of [Ac-225]-RTX-2358, a highly selective, FAP targeted radiotherapeutic labeled with Actinium 225, in patients with relapsed or refractory soft tissue sarcomas that express FAP."

Trial status • Soft Tissue Sarcoma

ATLAS: Actinium Therapy for Late-stage Aggressive Sarcomas (clinicaltrials.gov) - P1 | N=26 | Recruiting | Sponsor: Ratio Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

A PH/2 STUDY OF THE RADIOPHARMACEUTICAL [AC-225]RTX-2358 IN THE TREATMENT OF RELAPSED / REFRACTORY (R/R) SOFT TISSUE SARCOMA (STS) THE ATLAS STUDY - ACTINIUM THERAPY FOR LATE-STAGE AGGRESSIVE SARCOMAS (CTOS 2025) - "N/A"

Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CAFs • FAP